Sign in

CIK 0001623526 · Non-accelerated filer<br>Smaller reporting company

Stoke Therapeutics, Inc.

Sign in to watch
Ticker
STOK
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
471144582
Phone
781-430-8200
Business address
45 WIGGINS AVENUE, BEDFORD, MA, 01730
Former names
ASOthera Pharmaceuticals, Inc.
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Planned sale CHIEF MEDICAL OFFICER sold 1,795 shares at $30.58 ($54,891)
  4. 4 Planned sale CHIEF MEDICAL OFFICER sold 2,243 shares at $32.79 ($73,548)
  5. 4 Derivatives Options or other derivatives
  6. 3 Insider Initial Statement of Ownership
  7. 4 Planned sale CHIEF MEDICAL OFFICER sold 1,838 shares at $32.66 ($60,029)
  8. 4 Planned sale GENERAL COUNSEL & CORP SEC sold 9,293 shares at an average $33.69 ($313,038)
  9. 4 Planned sale CHIEF MEDICAL OFFICER sold 14,311 shares at an average $31.92 ($456,835)
  10. 4 Open-market sale Chief Financial Officer sold 4,578 shares at an average $32.14 ($147,145)
  11. 4 Open-market sale Chief Patient Officer sold 3,712 shares at an average $32.14 ($119,311)
  12. 4 Open-market sale GENERAL COUNSEL & CORP SEC sold 8,895 shares at an average $32.14 ($285,901)
  13. 4 Option exercise Chief Patient Officer acquired 10,000 shares (option exercise)
  14. 4 Option exercise Chief Financial Officer acquired 14,750 shares (option exercise)
  15. 4 Option exercise CHIEF MEDICAL OFFICER acquired 33,850 shares (option exercise)
  16. 4 Option exercise Director acquired 61,750 shares (option exercise)
  17. 4 Option exercise GENERAL COUNSEL & CORP SEC acquired 25,475 shares (option exercise)
  18. 4 Planned sale Director sold 605 shares at $36.80 ($22,264)
  19. 4 Planned sale Interim Executive Chair sold 4,355 shares at $40.00 ($174,214)
  20. 4 Planned sale Director sold 33,243 shares at $39.74 ($1,320,964)

Page 2 of 16 · 305 filings